IN8bio, Inc. (INAB, Financial) has unveiled encouraging long-term clinical data from its Phase 1 trial of INB-200, which is being tested on patients newly diagnosed with glioblastoma multiforme. The latest findings were shared on May 30 at the 2025 American Society of Clinical Oncology Annual Meeting. This Phase 1 study highlights that the innovative Drug Resistant Immunotherapy, involving genetically modified gamma-delta T cells, improves median progression-free survival (mPFS) to 16.1 months when used with standard chemotherapy, surpassing the historical 6.9 months seen with the SOC Stupp protocol.
Notably, the mPFS results already exceed the historical median overall survival (mOS) of 14.6 months linked to the standard protocol. Historically, a 2 to 3 month enhancement in mPFS is deemed significant and integral for FDA approval. Importantly, no severe toxicities or serious adverse reactions were reported, with most side effects being mild and similar to those caused by radiation and temozolomide. Furthermore, half of the patients who received repeated doses of INB-200 remained progression-free beyond 18 months, compared to none who received a single dose. Four patients receiving repeat doses are alive and progression-free for over two years, with no new relapses since the last update.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for IN8bio Inc (INAB, Financial) is $3.59 with a high estimate of $7.50 and a low estimate of $1.20. The average target implies an upside of 2,382.71% from the current price of $0.14. More detailed estimate data can be found on the IN8bio Inc (INAB) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, IN8bio Inc's (INAB, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
